A Phase 1 interventional study of Selpercatinib and Ranitidine in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 9 weeks, inclusive of screening period.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 160 mg Selpercatinib (Study Day 1).
Drug: Selpercatinib
Participants received 150 mg ranitidine twice a day orally for 11 days (Study Days 8 to 18) with a single oral dose of 160 mg Selpercatinib (Study Day 12).
Drug: Selpercatinib · Drug: Ranitidine
Participants received 40 mg omeprazole once daily for 11 days (Study Days 19 to 29) with a single oral dose of 160 mg Selpercatinib (Study Day 23).
Drug: Selpercatinib · Drug: Omeprazole
Administered orally.
Also known as: LY3527723, LOXO-292
Administered orally.
Administered orally.
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
PK: AUC0-t of Selpercatinib. The analysis of variance (ANOVA) model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric least squares (LS) means and the difference between treatment geometric LS means, as well as their corresponding 90% confidence intervals (CIs). The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
PK: AUC0-inf of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Percentage of Area Under the Plasma Concentration-Time Curve (AUC) That is Due to Extrapolation From Last Measurable Concentration to Infinity (%AUCextrap) of Selpercatinib
PK: %AUCextrap of Selpercatinib
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Maximum Observed Plasma Concentration (Cmax) of Selpercatinib
PK: Cmax of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Time of Maximum Observed Concentration (Tmax) of Selpercatinib
PK: Tmax of Selpercatinib
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Apparent Volume of Distribution (Vz/F)
PK: Vz/F of Selpercatinib
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib
PK: CL/F of Selpercatinib
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
PK: Apparent Terminal Elimination Half-life (t½) of Selpercatinib
PK: t½ of Selpercatinib
Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
| Milestone | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| Started | 20 | 0 | 0 |
| Received at least one dose of study drug | 20 | 0 | 0 |
| Completed | 20 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| Started | 0 | 20 | 0 |
| Completed | 0 | 17 | 0 |
| Not completed | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Milestone | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| Started | 0 | 0 | 17 |
| Completed | 0 | 0 | 17 |
| Not completed | 0 | 0 | 0 |
PK: AUC0-t of Selpercatinib. The analysis of variance (ANOVA) model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric least squares (LS) means and the difference between treatment geometric LS means, as well as their corresponding 90% confidence intervals (CIs). The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.
| hour*nanograms per milliliter(h*ng/mL) | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib | 21600 ± 31.4 | 19100 ± 31.9 | 21000 ± 27.4 |
PK: AUC0-inf of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.
| h*ng/mL | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib | 21800 ± 31.2 | 19900 ± 33.5 | 21100 ± 27.4 |
PK: %AUCextrap of Selpercatinib
| percentage of (%) of AUCextrap | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160mg Selpercatinib |
|---|---|---|---|
| PK: Percentage of Area Under the Plasma Concentration-Time Curve (AUC) That is Due to Extrapolation From Last Measurable Concentration to Infinity (%AUCextrap) of Selpercatinib | 0.337 (0.136 to 3.00) | 0.818 (0.137 to 2.02) | 0.612 (0.103 to 1.59) |
PK: Cmax of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.
| ng/mL | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| PK: Maximum Observed Plasma Concentration (Cmax) of Selpercatinib | 1650 ± 58.4 | 1330 ± 67.8 | 1220 ± 63.4 |
PK: Tmax of Selpercatinib
| hour | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| PK: Time of Maximum Observed Concentration (Tmax) of Selpercatinib | 2.00 (1.00 to 3.00) | 1.83 (1.00 to 24.00) | 3.00 (1.50 to 6.00) |
PK: Vz/F of Selpercatinib
| liter | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| PK: Apparent Volume of Distribution (Vz/F) | 259 ± 44.2 | 331 ± 59.1 | 300 ± 48.6 |
PK: CL/F of Selpercatinib
| liter per hour (L/h) | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib | 7.35 ± 31.2 | 8.03 ± 33.5 | 7.58 ± 27.4 |
PK: t½ of Selpercatinib
| hour | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| PK: Apparent Terminal Elimination Half-life (t½) of Selpercatinib | 24.4 ± 35.4 | 29.3 ± 33.5 | 27.4 ± 30.1 |
Collected over Baseline through Day 37. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 160 mg Selpercatinib | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 0/20 (0%) | 0/20 (0%) | 11/20 (55%) |
| 40 mg Omeprazole Dosed With 160 mg Selpercatinib | 0/17 (0%) | 0/17 (0%) | 4/17 (23.5%) |
| Event | 160 mg Selpercatinib | 150 mg Ranitidine Dosed With 160 mg Selpercatinib | 40 mg Omeprazole Dosed With 160 mg Selpercatinib |
|---|---|---|---|
| DysmenorrhoeaReproductive system and breast disorders | 0/4 | 1/4 | 0/3 |
| ConstipationGastrointestinal disorders | 3/20 | 2/20 | 2/17 |
| Abdominal distensionGastrointestinal disorders | 0/20 | 0/20 | 2/17 |
| DyspepsiaGastrointestinal disorders | 0/20 | 2/20 | 0/17 |
| HeadacheNervous system disorders | 0/20 | 2/20 | 1/17 |
| SomnolenceNervous system disorders | 0/20 | 2/20 | 0/17 |
| InsomniaPsychiatric disorders | 0/20 | 2/20 | 1/17 |
| Dry skinSkin and subcutaneous tissue disorders | 0/20 | 2/20 | 0/17 |
| Erectile dysfunctionReproductive system and breast disorders | 1/16 | 0/16 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 0/20 | 1/17 |
All participants who received at least one dose of study drug.
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 20 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 4 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 11 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Study Participants |
|---|---|
| United States | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Sep 2019, 1 month.
Results were first posted in Oct 2024, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib